VideoViral Hepatitis and Liver DiseaseHEP DART 2017Access to HIV, HBV, and HCV Antiviral Agents Globally | John Martin, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Global Strategies to Eliminate Hepatitis B (ICE-HBV) | Peter RevillView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition | Anna S. Lok, MD, DScView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017The French and European Approach Towards Hepatitis Elimination | Tarik Asselah, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Elimination of HCV: The DC Story | Henry Masur, MDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report) | Andrew Aronsohn, MDView Video
MHMargaret HellardAM, MBBS, FRACP, FAFPHM, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhDView Video
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Establishment of functional control and normalization of liver function in HBeAg negative chronic HBV infection following combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a.- Dr. A. VaillantView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Validation of a novel Transient Elastography for the measurement of liver fibrosis- Dr. J. DongView Slideset
VMVeronica MillerPhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Regulatory landscape for NASH- Veronica MillerView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells (not yet available)- Dr. E. ThomasView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years- Dr. R. HyerView Slideset
